Physician profile
Mark D Gibbons
NPI 1952484784
$1,015.44
in general payments reported to CMS, 2019-2025
12 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.43 · 2020: $74.41 · 2021: $121 · 2022: $46.51 · 2023: $283 · 2024: $288 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $453.36 | 2023-2025 | Inspire |
| Genzyme Corporation | $154.31 | 2021-2025 | |
| Stryker Corporation | $109.95 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $71.12 | 2021-2023 | Dupixent |
| Smith+Nephew, INC. | $52.04 | 2021-2024 | Tula |
| Aerin Medical INC. | $51.62 | 2024-2025 | |
| Alk-Abello, INC | $37.25 | 2021 | |
| Medtronic, INC. | $23.12 | 2023 | Pteye Parathyroid Detection System |
| Acclarent, INC | $20.07 | 2019 | |
| Olympus America INC. | $15.68 | 2021 | |
| Intersect Ent, INC. | $13.82 | 2019 | |
| Glaxosmithkline, LLC. | $13.10 | 2023 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gibbons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.